Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

6,155JPY
22 Nov 2017
Change (% chg)

-- (--)
Prev Close
¥6,155
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,031,344
52-wk High
¥6,464
52-wk Low
¥4,555

Latest Key Developments (Source: Significant Developments)

Takeda, Schrödinger announce multi-year, multi-target research collaboration
Thursday, 20 Jul 2017 09:00am EDT 

July 20 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::Takeda and Schrödinger announce multi-year, multi-target research collaboration.Says under novel collaboration approach, Schrödinger will autonomously lead discovery efforts.Says under terms of collaboration, Takeda will have option to exclusively license programs from Schrödinger.Takeda Pharmaceutical Co Ltd - additional financial details are not being disclosed.Takeda Pharmaceutical - economic terms include pre-clinical, clinical, and commercial milestones of up to $170 million per program, as well as royalties on future sales.  Full Article

Prana Biotechnology announces research collaboration with Takeda Pharmaceuticals
Monday, 17 Jul 2017 08:05pm EDT 

July 18 (Reuters) - Prana Biotechnology:announced a research collaboration with Takeda Pharmaceuticals International, Inc.  Full Article

Selexis announces commercial license agreement with Takeda
Tuesday, 27 Jun 2017 08:00am EDT 

June 27 (Reuters) - :Selexis announces commercial license agreement with Takeda for the development of fusion proteins.  Full Article

Takeda and Seattle Genetics announce positive results from phase 3 ECHELON-1 clinical trial
Monday, 26 Jun 2017 06:45am EDT 

June 26 (Reuters) - Seattle Genetics Inc :Takeda and Seattle Genetics announce positive results from phase 3 ECHELON-1 clinical trial evaluating Adcetris in frontline advanced hodgkin lymphoma.Says interim analysis of overall survival, key secondary endpoint, also trended in favor of Adcetris+AVD arm.Says safety profile of Adcetris+AVD in trial was consistent with that known for single-agent components of regimen.Says there was an increased incidence of febrile neutropenia and peripheral neuropathy in the Adcetris+AVD arm.Takeda and Seattle Genetics plan to submit trial results to regulatory authorities for approval in respective territories.phase 3 clinical trial met primary endpoint of statistically significant improvement in modified progression-free survival versus control arm.  Full Article

Swissmedic acceptes Takeda and Tigenix's file on Cx601 for review
Tuesday, 20 Jun 2017 01:18am EDT 

June 20 (Reuters) - TIGENIX NV ::TAKEDA <<<4502.T>>> AND TIGENIX ANNOUNCE THAT SWISSMEDIC HAS ACCEPTED FOR REVIEW THE FILE ON CX601 FOR THE TREATMENT OF COMPLEX PERIANAL FISTULAS IN CROHN’S DISEASE PATIENTS.  Full Article

Wilex says unit Heidelberg Pharma signs research agreement with Takeda
Monday, 19 Jun 2017 11:14am EDT 

June 19 (Reuters) - WILEX AG ::SUBSIDIARY HEIDELBERG PHARMA SIGNS EXCLUSIVE MULTI-TARGET RESEARCH AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT OF ANTIBODY TARGETED AMANITIN CONJUGATES.‍UNDER TERMS OF AGREEMENT, HEIDELBERG PHARMA WILL PRODUCE ANTIBODY TARGETED AMANITIN CONJUGATES (ATACS) USING ANTIBODIES FROM TAKEDA'S PROPRIETARY PORTFOLIO FOR UP TO THREE UNDISCLOSED TARGETS​.‍UNDER LICENSE AGREEMENT, HEIDELBERG PHARMA WOULD BE ELIGIBLE TO RECEIVE CLINICAL DEVELOPMENT, REGULATORY AND SALES-RELATED MILESTONE PAYMENTS OF UP TO USD 113 MILLION FOR EACH PRODUCT CANDIDATE, AS WELL AS ROYALTIES​.  Full Article

Takeda, Seattle Genetics announce Lancet publication
Wednesday, 7 Jun 2017 08:00am EDT 

June 7 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>: :Takeda and Seattle Genetics announce Lancet publication of phase 3 alcanza clinical trial data of adcetris (brentuximab vedotin) for CD30-positive cutaneous t-cell lymphoma.Takeda - ‍takeda plans to begin to submit data from alcanza trial to regulatory agencies in its territories in 2017​.Takeda - ‍Seattle Genetics plans to submit these data as part of a supplemental biologics license application to FDA in mid-2017​.  Full Article

Takeda Pharmaceutical announces further details of transformational pharmaceutical sciences partnership with Bushu
Monday, 15 May 2017 05:20am EDT 

May 15(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it has entered into an agreement for an absorption-type company split with its wholly-owned subsidiary, SPERA PHARMA, Inc. on May 15.Says subsidiary was established as a succeeding company on April 20.Says it plans to transfer a part of Pharmaceutical Sciences businesses of the co to Bushu Pharmaceuticals Ltd. .Says it will transfer all of the issued shares in succeeding company to Bushu Pharmaceuticals Ltd. based on the share transfer agreement, on July 1.  Full Article

Takeda Pharmaceutical to transfer partial pharmaceutical research businesses to succeeding company
Monday, 15 May 2017 04:20am EDT 

May 15 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:* Says it established a succeeding company on April 27.* Says it will transfer a part of Takeda's pharmaceutical research businesses to the succeeding company, effective July 1.  Full Article

Takeda announces FDA accelerated approval of ALUNBRIG
Friday, 28 Apr 2017 06:13pm EDT 

April 28 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::Takeda announces FDA accelerated approval of ALUNBRIG(brigatinib).Says continued approval for ALK+ metastatic NSCLC indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.Says serious adverse reactions occurred in 38% of patients in 90 mg group and 40% of patients in 90→180 mg group.Says fatal adverse reactions occurred in 3.7% of patients.Says the fatal adverse reactions consisted of pneumonia, sudden death, dyspnea, respiratory failure, pulmonary embolism, bacterial meningitis and urosepsis.Says FDA approval of ALUNBRIG was primarily based on results from pivotal phase 2 alta trial of brigatinib in adults.  Full Article

BRIEF-U.S. FDA provides new drug safety communication on Takeda's gout drug

* U.S. FDA says preliminary results from a safety clinical trial show increased risk of heart-related death with Febuxostat (Uloric) versus Allopurinol